Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYSTROKE: Pembrolizumab + SBRT vs SBRT Alone for Recurrent/Second Primary HNSCC
NCT03546582Phase 2Active, not recruiting
- Sponsor
- RTOG Foundation
- Start
- Nov 2018
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by RTOG Foundation. Primary endpoint: Progression Free Survival at 5 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03546582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546582.